文献类型：期刊文献

英文题名：A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action: The similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin

作者：Zhang, Chi[1];Ma, Shuangshuang[1];Wu, Jiahui[1];Luo, Linglong[1];Qiao, Sanyang[1];Li, Ruxin[1];Xu, Wenjuan[1];Wang, Nan[1];Zhao, Baosheng[2];Wang, Xiao[3];Zhang, Yuan[4];Wang, Xueyong[1]

第一作者：Zhang, Chi

通讯作者：Wang, XY[1]

机构：[1]Beijing Univ Chinese Med, Sch Chinese Meteria Med, Northeast Corner Intersect Sunshine South St & Ba, Beijing 102488, Peoples R China;[2]Beijing Univ Chinese Med, Beijing Res Inst Chinese Med, Beijing 100029, Peoples R China;[3]Qilu Univ Technol, Coll Pharm, Shandong Acad Sci, Jinan 250014, Shandong, Peoples R China;[4]Beijing Union Univ, Coll Biochem Engn, 18 Fatou Xifi Dist, Beijing 100023, Peoples R China

第一机构：Beijing Univ Chinese Med, Sch Chinese Meteria Med, Northeast Corner Intersect Sunshine South St & Ba, Beijing 102488, Peoples R China

通讯机构：[1]corresponding author), Beijing Univ Chinese Med, Sch Chinese Meteria Med, Northeast Corner Intersect Sunshine South St & Ba, Beijing 102488, Peoples R China.

年份：2020

卷号：159

外文期刊名：PHARMACOLOGICAL RESEARCH

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000566437600020)】；

基金：This work was supported by grants from the National Science & Technology Fundamental Resources Investigation Program of China (2018FY100700), the National Natural Science Foundation of China (81773841) and the Science & Technology Support Plan of Guizhou Province (2017MA6DRXM2320354).

语种：英文

外文关键词：Microbiome; Metabolomics; T2DM; Metformin; Ce-RS3

摘要：The relationship between gut microbiota and type 2 diabetes mellitus (T2DM) has drawn increasing attention, and the benefits of various treatment strategies, including nutrition, medication and physical exercise, maybe microbially-mediated. Metformin is a widely used hypoglycemic agent, while resistant starch (RS) is a novel dietary fiber that emerges as a nutritional strategy for metabolic disease. However, it remains unclear as to the potential degree and interactions among gut microbial communities, metabolic landscape, and the anti-diabetic effects of metformin and RS, especially for a novel type 3 resistant starch from Canna edulis (Ce-RS3). In the present study, T2DM rats were administered metformin or Ce-RS3, and the changes in gut microbiota and serum metabolic profiles were characterized using 16S-rRNA gene sequencing and metabolomics, respectively. After 11 weeks of treatment, Ce-RS3 exhibited similar anti-diabetic effects to those of metformin, including dramatically reducing blood glucose, ameliorating the response to insulin resistance and glucose tolerance test, and relieving the pathological damage in T2DM rats. Interestingly, the microbial and systemic metabolic dysbiosis in T2DM rats was effectively modulated by both Ce-RS3 and, to a lesser extent, metformin. The two treatments increased the gut bacterial diversity, and supported the restoration of SCFA-producing bacteria, thereby significantly increasing SCFAs levels. Both treatments simultaneously corrected 16 abnormal metabolites in the metabolism of lipids and amino acids, many of which are microbiome-related. PICRUSt analysis and correlation of SCFAs levels with metabolomics data revealed a strong association between gut microbial and host metabolic changes. Strikingly, Ce-RS3 exhibited better efficacy in increasing gut microbiota diversity with a peculiar enrichment of Prevotella genera. The gut microbial properties of Ce-RS3 were tightly associated with the T2DM-related indexes, showing the potential to alleviate diabetic phenotype dysbioses, and possibly explaining the greater efficiency in improving metabolic control.